`1600 PTAB & Beyond
`
`SIGNIFICANT PATENT DECISIONS AND DEVELOPMENTS AFFECTING THE LIFE SCIENCES
`INDUSTRY
`
`How reliable are trial dates relied on by the PTAB in the
`Fintiv analysis?
`
`By Andrew T. Dufresne, Nathan K. Kelley & Lori Gordon on October 29, 2021
`
`In recent years, the Patent Trial and Appeal Board has frequently declined to institute IPRs
`for procedural reasons unrelated to a petition’s substantive strength. In particular, the Board
`has increasingly denied petitions in view of related, parallel litigation that it perceives as so
`far advanced that it would be most efficient to deny institution and leave patentability issues
`to be resolved in the other forum. Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 11
`(PTAB Mar. 20, 2020) (Precedential). Key among the factors guiding those Fintiv denials is
`whether and to what extent the other proceeding’s trial date is scheduled to precede the
`Board’s deadline for issuing a final written decision, i.e., Fintiv factor two. Id. at 9.
`
`But how reliable are those trial dates?
`
`The Board “generally take[s] trial courts’ trial schedules at face value absent some strong
`evidence to the contrary.” Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 15, at 12-13
`(PTAB May 13, 2020) (Informative). Some have questioned that approach, citing limited
`data sets that suggested such trial dates often change and therefore present an unreliable
`basis for denying institution. We took a more comprehensive look at this question by
`identifying all discretionary denials that were based on parallel litigation and issued between
`May and October 2020. That six-month period opened the same month that Fintiv was
`designated precedential and ended approximately one year ago, allowing us to evaluate
`what actually happened over the intervening year when an IPR otherwise would have taken
`place and reached a final written decision within the 12-month timeframe required by statute.
`
`SAMSUNG EXHIBIT 1024
`Samsung Electronics Co., Ltd. and Dell Technologies Inc. v. MYPAQ Holdings Ltd.
` IPR2022-00311, Page 1
`
`
`
`The Board was almost always wrong when predicting trial dates in
`parallel litigation
`
`Our results confirm the prior criticism. Out of 55 discretionary denials, only seven cited a trial
`date that proved accurate.[1] Notably, in four of those, the cited date was correct because
`trial had already occurred when the Board denied institution. Apple Inc. v. Unwired Planet
`Int’l Ltd., IPR2020-00642, Paper 15 (PTAB Sept. 9, 2020); Apple Inc. v. Optis Wireless Tech.,
`LLC, IPR2020-00466, Paper 13 (PTAB Sept. 15, 2020); Apple Inc. v. Optis Cellular Tech.,
`
`LLC, IPR2020-00465, Paper 13 (PTAB Sept. 17, 2020); Amazon.com, Inc. v. Vocalife LLCVocalife LLC,,
`
`IPR2020-00864, Paper 22 (PTAB Oct. 28, 2020). When evaluating future trial dates, theIPR2020-00864, Paper 22 (PTAB Oct. 28, 2020). When evaluating future trial dates, the
`
`Board was wrong 94% of the time (48/51).Board was wrong 94% of the time (48/51).
`
`
`
`The discrepancies were often substantial. Out of the 51 cases where the Board relied on aThe discrepancies were often substantial.
`
`predicted future trial date, only three occurred on time. For the others, one was delayed by
`less than one month, five were delayed by 1-3 months, 17 were delayed by 3-6 months,
`three were delayed by 6-12 months, and seven remain pending pre-trial, well beyond the
`
`SAMSUNG EXHIBIT 1024
`Samsung Electronics Co., Ltd. and Dell Technologies Inc. v. MYPAQ Holdings Ltd.
` IPR2022-00311, Page 2
`
`
`
`earlier trial date the Board accepted at face value. Another 15 litigations were terminated
`without any ruling on validity (for reasons including settlement, bankruptcy, and summary
`judgment on other issues).
`
`Conclusions
`
`The Board’s reliance on scheduled trial dates has proven remarkably inaccurate, and our
`results contradict the Board’s stated practice under Fintiv of simply accepting nominal trial
`dates at face value under Fintiv factor two. Trial dates in patent litigation are not stable and
`make a very poor barometer for evaluating the potential efficiency of denying institution
`based on a parallel proceeding.
`
` [1] Our methodology counted AIA trials individually, including when multiple petitions
`were related to the same parallel litigation. The percentages remained approximately the
`same if related AIA trials were grouped by litigation, with errors in predicting future trial dates
`occurring in 95% of related proceedings.
`
`1600 PTAB & Beyond
`Significant Patent Decisions and Developments Affecting The Life Sciences Industry
`
`SAMSUNG EXHIBIT 1024
`Samsung Electronics Co., Ltd. and Dell Technologies Inc. v. MYPAQ Holdings Ltd.
` IPR2022-00311, Page 3
`
`
`
`Copyright © 2022, Perkins Coie LLP. All Rights Reserved.
`
`SAMSUNG EXHIBIT 1024
`Samsung Electronics Co., Ltd. and Dell Technologies Inc. v. MYPAQ Holdings Ltd.
` IPR2022-00311, Page 4
`
`